# US 2023/0054039 A1 · Method of treating her2-positive breast cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054039 A1
- Document ID: US20230054039A1
- Status: Published application
- Kind: A1
- Application number: 17/815,849
- Filed: 2022-07-28
- Published: 2023-02-23
- Earliest claimed: 2021-07-28
- Assignees: University of Cincinnati
- Applicants: University of Cincinnati
- Inventors: Jun-Lin Guan; Mingang Hao
- Web page: https://patentgrep.com/patent/US20230054039A1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating human epidermal growth factor receptor 2 (HER2)-positive breast cancer in a subject in need thereof is provided, including administering to the subject an effective amount of a therapeutic agent that inhibits a nucleic acid that encodes FAK family-interacting protein of 200 kDa (FIP200). Also provided is a method of inhibiting metastasis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer in a subject.

## Claims

### Claim 1

A method of treating human epidermal growth factor receptor 2 (HER2)-positive breast cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a therapeutic agent that inhibits a nucleic acid that encodes FAK family-interacting protein of 200 kDa (FIP200).

### Claim 2 (depends on 1)

The method according to claim 1, wherein the HER2-positive breast cancer is metastatic.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the therapeutic agent is a gene editing agent.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the gene editing agent is selected from the group consisting of a CRISPR-Cas system, a transcription activator-like effector nuclease (TALEN), and a zing finger nuclease (ZFN).

### Claim 5 (depends on 1)

The method according to claim 1, wherein the therapeutic agent is an siRNA or an shRNA,

### Claim 6 (depends on 5)

The method according to claim 5, wherein the shRNA is selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the method inhibits FIP200-mediated autophagy in a HER2-positive breast cancer cell of the subject.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the method reduces expression of HER2 on a plasma membrane of a HER2-positive breast cancer cell of the subject.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the method stimulates release of small extracellular vesicles (sEVs) from a HER2-positive breast cancer cell of the subject.

### Claim 10 (depends on 9)

The method according to claim 9, wherein a vesicular membrane of the sEV comprises HER2.

### Claim 11 (depends on 1)

The method according to claim 1, further comprising administering to the subject an effective amount of a second therapeutic agent.

### Claim 12 (depends on 12)

The method according to claim 12, wherein the second therapeutic agent is selected from the group consisting of ado-trastuzumab emtansine, fam-trastuzumab deruxtecan, trastuzumab, trastuzumab/hyaluronidase, lapatinib, margetuximab, neratinib, pertuzumab, pertuzumab/trastuzumab/hyaluronidase, tucatinib, tamoxifen, anastrozole, letrozole, doxorubicin, epirubicin, paclitaxel, radiation therapy, and combinations thereof.

### Claim 13

A method of inhibiting metastasis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a therapeutic agent that inhibits FAK family-interacting protein of 200 kDa (FIP200)-mediated autophagy.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the therapeutic agent inhibits a nucleic acid that encodes FIP200.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the therapeutic agent is a gene editing agent.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the gene editing agent is selected from the group consisting of a CRISPR-Cas system, a transcription activator-like effector nuclease (TALEN), and a zing finger nuclease (ZFN).

### Claim 17 (depends on 16)

The method according to claim 16, wherein the CRISPR-Cas system comprises a CRISPR-associated endonuclease and a guide RNA (sgRNA), wherein the sgRNA targets FIP200.

### Claim 18 (depends on 14)

The method according to claim 14, wherein the therapeutic agent is an siRNA or an shRNA,

### Claim 19 (depends on 17)

The method according to claim 17, wherein the shRNA is selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.

### Claim 20 (depends on 13)

The method according to claim 13, wherein the method reduces expression of HER2 on a plasma membrane of a HER2-positive breast cancer cell of the subject.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the method stimulates release of small extracellular vesicles (sEVs) from a HER2-positive breast cancer cell of the subject.

### Claim 22 (depends on 21)

The method according to claim 21 wherein a vesicular membrane of the sEV comprises HER2.

### Claim 23 (depends on 13)

The method according to claim 13, further comprising administering to the subject an effective amount of a second therapeutic agent.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the second therapeutic agent is selected from the group consisting of ado-trastuzumab emtansine, fam-trastuzumab deruxtecan, trastuzumab, trastuzumab/hyaluronidase, lapatinib, margetuximab, neratinib, pertuzumab, pertuzumab/trastuzumab/hyaluronidase, tucatinib, tamoxifen, anastrozole, letrozole, doxorubicin, epirubicin, paclitaxel, radiation therapy, and combinations thereof.
